Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 04 2024
Historique:
received: 16 01 2024
accepted: 05 04 2024
medline: 19 4 2024
pubmed: 18 4 2024
entrez: 17 4 2024
Statut: epublish

Résumé

In this study, we aimed to establish a technique for intraprostatic implantation of prostate cancer (PCa) spheroids and to identify the impact of three-dimensional organization of PCa cells on tumor progression and metastasis in a representative in vivo model. 40,000 LNCaP cells were implanted into the prostate of immunodeficient SCID mice either as single cells (n = 8) or as preformed 3D spheroids (n = 8). For a follow up of 20 weeks, tumor growth was monitored by serum PSA and high-resolution 3D ultrasonography. Eventually, animals were sacrificed and autopsied. The organ dissects were analyzed for the presence of metastases by histology (H&E) and immunohistochemistry (AMACR, AR, Ki-67, CK5, CK8, E-Cadherin, Vimentin). Solid intraprostatic tumors developed in 50% of mice after spheroid implantation and in 50% of mice after implantation of a single cells. Primary tumors of LNCaP spheroids evolved earlier, exhibiting a shorter tumor doubling time whilst developing larger tumor volumes, which was reflected by a higher immunohistochemical expression of Ki-67 and AR, too. Spheroid tumors established lung and lymph node metastases in 75% of mice, in contrast to 50% of mice after single cell implantation. Our technique enables a variety of studies regarding the influence of the tumor microenvironment on PCa progression.

Identifiants

pubmed: 38632341
doi: 10.1038/s41598-024-59052-0
pii: 10.1038/s41598-024-59052-0
pmc: PMC11024136
doi:

Substances chimiques

Ki-67 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8835

Informations de copyright

© 2024. The Author(s).

Références

Nat Rev Urol. 2023 Mar;20(3):158-178
pubmed: 36451039
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):179-92
pubmed: 11033305
Biotechnol J. 2008 Oct;3(9-10):1172-84
pubmed: 18566957
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Mol Cell Cardiol. 2011 Feb;50(2):290-5
pubmed: 21047516
Prostate. 1998 Apr 1;35(1):1-10
pubmed: 9537593
Cancer Res. 1983 Apr;43(4):1809-18
pubmed: 6831420
Cell Commun Signal. 2020 Jan 24;18(1):11
pubmed: 31980029
BJU Int. 2003 Jun;91(9):789-94
pubmed: 12780833
Am J Cancer Res. 2022 Mar 15;12(3):1116-1128
pubmed: 35411223
Prostate. 2015 Oct;75(14):1526-37
pubmed: 26074274
Clin Cancer Res. 1999 Oct;5(10 Suppl):3171s-3176s
pubmed: 10541360
Prostate. 2018 Jun;78(9):664-675
pubmed: 29572953
MAGMA. 2005 Dec;18(6):293-301
pubmed: 16328228
Immunotherapy. 2011 Nov;3(11):1367-84
pubmed: 22053887
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2021 Mar 4;11(1):5118
pubmed: 33664329
Nat Rev Urol. 2020 Jan;17(1):11-27
pubmed: 31827264
Nature. 2003 Aug 21;424(6951):870-2
pubmed: 12931155
Oncotarget. 2016 Mar 22;7(12):14639-58
pubmed: 26840259
Mol Carcinog. 2015 Jul;54(7):554-65
pubmed: 24347249
J Cancer Res Clin Oncol. 2019 Mar;145(3):551-559
pubmed: 30474758
Anticancer Res. 1998 Nov-Dec;18(6A):4147-58
pubmed: 9891460
Yakugaku Zasshi. 2008 Jan;128(1):37-44
pubmed: 18176054
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9
pubmed: 11531144
Oncogene. 2013 Sep 12;32(37):4343-54
pubmed: 23085755
Am J Pathol. 2012 Feb;180(2):473-83
pubmed: 22197383
Adv Drug Deliv Rev. 2014 Dec 15;79-80:214-21
pubmed: 24816064
Biomed Eng Online. 2016 Apr 27;15:46
pubmed: 27121383
Sci Rep. 2020 Jul 28;10(1):12575
pubmed: 32724081
Prostate. 2013 Sep;73(12):1251-62
pubmed: 23740600
Tumour Biol. 2016 Feb;37(2):2481-96
pubmed: 26385771
Tissue Eng. 2004 Jul-Aug;10(7-8):1266-76
pubmed: 15363181

Auteurs

Julius Lars Daniel Bastian (JLD)

Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstr. 100 Gebäude 6, 66424, Homburg, Germany.

Philip Zeuschner (P)

Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstr. 100 Gebäude 6, 66424, Homburg, Germany.

Michael Stöckle (M)

Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstr. 100 Gebäude 6, 66424, Homburg, Germany.

Kerstin Junker (K)

Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstr. 100 Gebäude 6, 66424, Homburg, Germany.

Johannes Linxweiler (J)

Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstr. 100 Gebäude 6, 66424, Homburg, Germany. johannes.linxweiler@uks.eu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH